Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 5/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.32 |
| ▸ | CDK1 | P06493 | 4/20 | 0.32 |
| ▸ | CDK4 | P11802 | 4/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.32 |
| ▸ | CCND1 | P24385 | 4/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.32 |
| ▸ | CDK2 | P24941 | 4/20 | 0.32 |
| ▸ | CCND2 | P30279 | 4/20 | 0.32 |
| ▸ | CCND3 | P30281 | 4/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.32 |
| ▸ | MGAM | O43451 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537532 | 0.87 | PDE5A (0.32) | — | |
| SCHEMBL13664128 | 0.86 | RARA (0.32) | RARARARBFFAR1FFAR4THRA | |
| SCHEMBL30699313 | 0.77 | PDE3B (0.38) | GCGRFFAR1FFAR4 | |
| SCHEMBL4300317 | 0.77 | PDE3B (0.38) | GCGRFFAR1FFAR4 | |
| SCHEMBL13664127 | 0.76 | FFAR4 (0.39) | RARARARBFFAR1FFAR4THRA | |
| SCHEMBL4309431 | 0.75 | GAA (0.41) | FFAR4THRATHRBMGAMGAA | |
| SCHEMBL13664504 | 0.72 | — | — | |
| SCHEMBL5532894 | 0.72 | — | — | |
| SCHEMBL1582737 | 0.70 | ALDH1A1 (0.40) | RARARARBTHRATHRBCCNB2 | |
| SCHEMBL12829236 | 0.70 | MCL1 (0.41) | RARARARBFFAR1FFAR4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1870403-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING -AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & COMPANY, LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | BCAT1, BCAT2, AADAT | GCGR 4696/4885RARA 1570/4885RARB 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.